Sign In
Buy ZYME
$24.35
+0.240 (+1.00%)
At Close: Jun 03, 2026
Neoleukin Therapeutics (NASDAQ:NLTX) & Zymeworks (NASDAQ:ZYME) Critical Contrast
01:24am, Monday, 06'th Apr 2026
Neoleukin Therapeutics (NASDAQ: NLTX - Get Free Report) and Zymeworks (NASDAQ: ZYME - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two
Zymeworks Appoints Kristin Stafford as Chief Financial Officer
06:00am, Wednesday, 01'st Apr 2026
VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pi
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
06:00am, Monday, 30'th Mar 2026
VANCOUVER, British Columbia, March 30, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pi
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Tuesday, 24'th Mar 2026
VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pi
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
07:46am, Wednesday, 18'th Mar 2026
VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pip
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
05:02pm, Tuesday, 17'th Mar 2026
VANCOUVER, British Columbia , March 17, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pi
Zymeworks Inc. $ZYME Shares Sold by Citigroup Inc.
03:36am, Monday, 09'th Mar 2026
Citigroup Inc. trimmed its position in shares of Zymeworks Inc. (NASDAQ: ZYME) by 24.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Co
Zymeworks FY25 Review: From Milestone Volatility To 2026 Upside
10:45am, Wednesday, 04'th Mar 2026
Zymeworks Inc. (ZYME) reported weak Q4 results, highlighting the volatility of its milestone-driven revenue model and underscoring execution risk ahead of commercialization. Despite top-line misses, Z
Zymeworks Inc. (NASDAQ:ZYME) Given Average Rating of “Moderate Buy” by Brokerages
04:13am, Wednesday, 04'th Mar 2026
Shares of Zymeworks Inc. (NASDAQ: ZYME - Get Free Report) have been assigned an average rating of "Moderate Buy" from the fourteen ratings firms that are covering the stock, Marketbeat Ratings reports
Zymeworks Q4 Earnings Call Highlights
01:34am, Wednesday, 04'th Mar 2026
Zymeworks (NASDAQ: ZYME) executives used the company's fourth-quarter 2025 results call to highlight updated clinical data for its partnered HER2 antibody zanidatamab, outline a new royalty-backed fin
Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript
09:17pm, Monday, 02'nd Mar 2026
Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript
Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates
08:15am, Monday, 02'nd Mar 2026
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.31 per share a year ago.
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
06:10am, Monday, 02'nd Mar 2026
NEW YORK and VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Zymeworks Inc. (Nasdaq: ZYME) today announced an agreement for $250 million in fundin
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
06:01am, Monday, 02'nd Mar 2026
VANCOUVER, British Columbia and NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) and Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $250 million in fundi
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
06:00am, Monday, 02'nd Mar 2026
VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pi
